Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 3.78 2.72% 0.10
SPPI closed up 2.72 percent on Thursday, August 13, 2020, on 60 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up
Historical SPPI trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 2.72%
NR7 Range Contraction 2.72%
Upper Bollinger Band Walk Strength 2.72%
Wide Bands Range Expansion 2.72%
Bearish Engulfing Bearish 2.72%
Upper Bollinger Band Walk Strength 2.72%
Outside Day Range Expansion 2.72%

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Medicine Biotechnology Health Cancer Chemotherapy Radiation Prostate Cancer Solid Tumor Osteosarcoma Cancer Therapy Non Muscle Invasive Bladder Cancer Oncology Products Treating Cancer Neutropenia Ozarelix

Is SPPI a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 10.57
52 Week Low 1.7422
Average Volume 2,585,786
200-Day Moving Average 4.11
50-Day Moving Average 3.32
20-Day Moving Average 3.49
10-Day Moving Average 3.60
Average True Range 0.30
ADX 27.36
+DI 32.80
-DI 16.66
Chandelier Exit (Long, 3 ATRs ) 3.85
Chandelier Exit (Short, 3 ATRs ) 3.82
Upper Bollinger Band 4.07
Lower Bollinger Band 2.91
Percent B (%b) 0.75
BandWidth 33.19
MACD Line 0.13
MACD Signal Line 0.10
MACD Histogram 0.0316
Fundamentals Value
Market Cap 297.81 Million
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -3.78
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.07
Resistance 3 (R3) 4.05 3.95 4.02
Resistance 2 (R2) 3.95 3.87 3.95 4.00
Resistance 1 (R1) 3.86 3.83 3.91 3.88 3.99
Pivot Point 3.76 3.76 3.78 3.76 3.76
Support 1 (S1) 3.67 3.68 3.72 3.69 3.57
Support 2 (S2) 3.57 3.64 3.57 3.56
Support 3 (S3) 3.48 3.57 3.54
Support 4 (S4) 3.50